OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 15:23 UTC. Every row links to its source record.

ETV1 ETS variant transcription factor 1

ENSG00000006468 · protein coding · Open Targets profile

Transcriptional activator that binds to DNA sequences containing the consensus pentanucleotide 5'-CGGA[AT]-3' (PubMed:7651741). Required for olfactory dopaminergic neuron differentiation; may directly activate expression of tyrosine hydroxylase (TH) (By similarity). {ECO:0000250|UniProtKB:P41164, ECO:0000269|PubMed:7651741}.

In 14 of 15 cancers, the evidence for ETV1 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751benign prostatic hyperplasiabenign prostatic hyperplasiabenign prostatic hyperplasia: somatic 0.61benign prostatic hyperplasia: germline 0.43prostate carcinomaprostate carcinomaprostate carcinoma: somatic 0.61lung carcinomalung carcinomalung carcinoma: somatic 0.61prostate adenocarcinomaprostate adenocarcinomaprostate adenocarcinoma: somatic 0.61esophageal adenocarcinomaesophageal adenocarcinomaesophageal adenocarcinoma: somatic 0.61Ewing sarcomaEwing sarcomagastric carcinomagastric carcinomagastric carcinoma: somatic 0.61acinar prostate mucinous adenocarcinomaacinar prostate mucinous adenocarcinomaacinar prostate mucinous adenocarcinoma: somatic 0.61malignant soft tissue neoplasmmalignant soft tissue neoplasmmalignant soft tissue neoplasm: somatic 0.61bile duct carcinomabile duct carcinomabile duct carcinoma: somatic 0.61lymphoid neoplasmlymphoid neoplasmlymphoid neoplasm: somatic 0.61ovarian endometrioid adenocarcinoma wit…ovarian endometrioid adenocarcinoma with squamous differentiationovarian endometrioid adenocarcinoma with squamous differentiation: somatic 0.61acinar prostate adenocarcinoma, foamy g…acinar prostate adenocarcinoma, foamy gland variantacinar prostate adenocarcinoma, foamy gland variant: somatic 0.61extraskeletal Ewing sarcoma/peripheral …extraskeletal Ewing sarcoma/peripheral primitive neuroectodermal tumorextraskeletal Ewing sarcoma/peripheral primitive neuroectodermal tumor: somatic 0.61kidney neoplasmkidney neoplasmkidney neoplasm: somatic 0.61

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

PROTAC
UniProt Ubiquitination

gnomAD loss of function constraint: o/e 0.4334999918937683 (upper bound 0.5978099703788757). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of ETV1's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of ETV1's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.